| Outcome Measures: |
Primary: Effect of liraglutide on fatty liver content evaluated by proton-spectroscopy (1H-spectroscopy and lipoprotein kinetics, in patients with type 2 diabetes, Before and after 6 month-treatment with liraglutide (1.2 mg/day)|Effects of liraglutide on Very Low Density Lipoprotein 1 (VLDL1) apolipoprotein B (apoB) production rate, Before and after 6 month-treatment with liraglutide (1.2 mg/day)|Effects of liraglutide on Very Low Density Lipoprotein 2 (VLDL2) apolipoprotein B (apoB) production rate, Before and after 6 month-treatment with liraglutide (1.2 mg/day)|Effects of liraglutide on Intermediate Density Lipoprotein (IDL) apolipoprotein B (apoB) production rate, Before and after 6 month-treatment with liraglutide (1.2 mg/day)|Effects of liraglutide on Low Density Lipoprotein (LDL) apolipoprotein B (apoB) production rate, Before and after 6 month-treatment with liraglutide (1.2 mg/day)|Effects of liraglutide on High Density Lipoprotein (HDL) apolipoprotein A1 (apoA1) production rate, Before and after 6 month-treatment with liraglutide (1.2 mg/day)|Effects of liraglutide on Very Low Density Lipoprotein 1 (VLDL1) apolipoprotein B (apoB) fractional catabolic rate, Before and after 6 month-treatment with liraglutide (1.2 mg/day)|Effects of liraglutide on Very Low Density Lipoprotein 2 (VLDL2) apolipoprotein B (apoB) fractional catabolic rate, Before and after 6 month-treatment with liraglutide (1.2 mg/day)|Effects of liraglutide on Intermediate Density Lipoprotein (IDL) apolipoprotein B (apoB) fractional catabolic rate, Before and after 6 month-treatment with liraglutide (1.2 mg/day)|Effects of liraglutide on Low Density Lipoprotein (LDL) apolipoprotein B (apoB) fractional catabolic rate, Before and after 6 month-treatment with liraglutide (1.2 mg/day)|Effects of liraglutide on High Density Lipoprotein (HDL) apolipoprotein A1 (apoA1) fractional catabolic rate, Before and after 6 month-treatment with liraglutide (1.2 mg/day) | Secondary: Modification of body weight, Modification of weight, induced by liraglutide 1.2 mg/d therapy., Before and after 6 month-treatment with liraglutide (1.2 mg/day)|Modification of subcutaneous fat by Magnetic Resonance Imaging (MRI), Modification of subcutaneous fat by MRI induced by liraglutide 1.2mg/d therapy, Before and after 6 month-treatment with liraglutide (1.2 mg/day)|Modification of visceral fat by Magnetic Resonance Imaging (MRI), Modification of visceral fat by MRI induced by liraglutide 1.2mg/d therapy, Before and after 6 month-treatment with liraglutide (1.2 mg/day)
|
